U.S.A.latest news

H A P P Y THANKSGIVING Don't let Food-borne Illnesses spoil your Holiday plans. Follow these tips to make sure your Thanksgiving meal is both delicious and safe to serve! L E A R N M O R E CLEAN, SEPARATE, COOK AND CHILL Get the Facts! STAY SAFE! Each year millions of people get sick from food illnesses. Food illness can cause you to feel like you have the flu. Use the tips provided in this free publication to ensure you have a very Happy Thanksgiving! ORDER NOW

This message was sent to politikimx@yahoo.gr from: US Government Publishing Office | pueblo@gpo.gov | GPO | 31451 United Ave | Pueblo, CO 81001 Goya Voluntary Recall of Adobo Because of Possible Health Risk Goya de Puerto Rico is recalling 28 ounces Adobo with Cumin Seasoning and 28 ounces Adobo with Pepper Seasoning because they have the potential to be contaminated with Salmonella, an organism which can cause serious and sometimes fatal infections in young children, frail or elderly people, and others with weakened immune system. No illnesses have been reported to date. 661 cases of these products were distributed in Puerto Rico through retail stores. Goya Adobo with Cumin Seasoning is package in 28 ounces plastic jar with green cap with mark "Best by Date 10/18/22''. Goya Adobo with Pepper Seasoning is package in 28 ounces plastic jar with red cap with mark "Best by Date 10/23/22".MedWatch - The FDA Safety Information and Adverse Event Reporting Program Limbrel Capsules by Primus Pharmaceuticals: FDA Advisory - Linked to Potentially Life-Threatening Health Problems [Posted 11/21/2017] AUDIENCE: Consumer, Health Professional ISSUE: The FDA is investigating serious adverse events involving Limbrel, a product in capsule form currently being marketed as a medical food to manage the metabolic processes associated with osteoarthritis. While a range of adverse events have been reported, two serious and potentially life-threatening medical conditions are among them: drug-induced liver injury and hypersensitivity pneumonitis. In total, the FDA has received 194 adverse event reports regarding Limbrel, of those, 57 of the cases contained sufficient information to analyze in detail whether Limbrel was associated with an adverse event; 30 of these contained sufficient information to use the Council for International Organizations of Medical Sciences (CIOMS) causality assessment method to determine the likelihood that an association between the consumption of Limbrel and the adverse events reported exists. BACKGROUND: Limbrel is marketed by Primus Pharmaceuticals Inc., Scottsdale, AZ. Limbrel is available in capsule form in two dosages: Limbrel250 and Limbrel500. The labeling states that the products contain two types of flavonoids: baicalin (from Scutellaria baicalensis) and catechin (from Acacia catechu). Both dosages also contain zinc. Claims made on the product label and in labeling indicate that Limbrel is intended to manage the metabolic processes associated with osteoarthritis. On November 8, 2017, the FDA contacted Primus Pharmaceuticals regarding the adverse events and requested information about the formula for Limbrel. The formula is being reviewed by the FDA. In the interim, the agency is alerting consumers and health care providers about the potential impact to health and advising consumers not to use Limbrel. The FDA is continuing to investigate Primus Pharmaceuticals and the manufacturing process for Limbrel, and will share updates as they become available. RECOMMENDATION: For Consumers: If you are taking Limbrel, immediately stop taking it and contact your health care provider.  If you have experienced any of the above-mentioned symptoms or other health problems while taking Limbrel, work with your health care provider to report your symptoms to the FDA through MedWatch. For Health Professionals: Health care providers who are aware that their patients are taking Limbrel should advise them to immediately stop taking the product. If your patients have experienced any of the above-mentioned symptoms or other health problems while taking Limbrel, the FDA encourages you to work with them to provide clinical information through MedWatch. Healthcare professionals and patients are encouraged to report adverse events or side effects related to the use of these products to the FDA's MedWatch Safety Information and Adverse Event Reporting Program: Complete and submit the report Online: www.fda.gov/MedWatch/report Download form or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178 Read the MedWatch Safety Alert, including a link to the FDA Drug Safety Communication, at:https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm586111.htm Let Us Know in One Simple Step Dear teacher and educator, We periodically review our email lists to make sure we're not sending unwanted emails, and we noticed you haven't opened an email from us in a while. Please on the below link by December 30  if you'd like to continue to receive emails from us, otherwise we'll remove you from our list. We hope you stay with us! Thank you, The USAGov Team Προς politikimx@yahoo.gr  Σήμερα στις 8:15 μ.μ. FTC Issues Annual Report On Ethanol Market Concentration 2017 The Federal Trade Commission has issued its 2017 Report on Ethanol Market Concentration, an annual report required by the Energy Policy Act of 2005 “to determine whether there is sufficient competition among industry participants to avoid price-setting and other anticompetitive behavior.” As in prior years, the 2017 report concludes that “the low level of concentration and large number of market participants in the U.S. ethanol production industry continue to suggest that the exercise of market power to set prices, or to coordinate on price and output levels, is unlikely.” The Commission vote to approve the report was 2-0. (FTC File No. P063000; the staff contact is Steven Couper, Bureau of Competition, 202-326-3349). The Federal Trade Commission works to promote competition, and protect and educate consumers. You can learn more about how competition benefits consumers or file an antitrust complaint. Like the FTC on Facebook, follow us on Twitter, read our blogs and subscribe to press releases for the latest FTC news and resources. Statement of Acting FTC Chairman Maureen K. Ohlhausen on Restoring Internet Freedom and Returning FTC Competition and Consumer Protections to Broadband Subscribers Today, Federal Communications Commission Chairman Ajit Pai circulated to FCC Commissioners a draft order in the Restoring Internet Freedom proceeding. Acting Federal Trade Commission Chairman Maureen K. Ohlhausen provided the following statement: “I am pleased to see progress on this important matter. The FTC has long applied its competition and consumer protection expertise to network neutrality issues. The FTC also participated in the FCC’s proceeding, and I am gratified that my comments and those of FTC staff appear to have been taken into consideration in the development of this order. I look forward to reading the full draft order. The FTC stands ready to protect broadband subscribers from anticompetitive, unfair, or deceptive acts and practices just as we protect consumers in the rest of the Internet ecosystem.” FCC Chairman Pai has announced that a draft of the order will be made public on Wednesday, Nov. 22, 2017. The FCC plans to vote on the report and order on December 14, 2017. Online Lingerie Marketer Prohibited from Deceiving Shoppers About Negative-Option Programs An online lingerie marketer has agreed to return more than $1.3 million to customers to settle Federal Trade Commission charges that it deceived shoppers who enrolled in a negative-option membership program offering discounts and other benefits, and made it hard for them to cancel their memberships. According to the FTC, AdoreMe Inc.’s “VIP” membership program cost $39.95 per month – unless, in the first five days of each month, a member bought something or clicked an online button to “skip” buying that month. The company’s website stated, “If you do not make a purchase or skip the month by the 5th, you’ll be charged a $39.95 store credit that can be used anytime to buy anything on Adore Me.” The FTC alleges that, despite explicit promises that consumers would be able to use their store credits “anytime,” from at least May 2015 to May 2016, AdoreMe took unused credit amounts away from consumers who cancelled their memberships or initiated chargebacks with financial institutions to dispute their transactions with the company. Despite discontinuing this practice in May 2016, the company has not made full refunds to all affected consumers. AdoreMe Inc., also doing business as Adore Me and Adoreme.com Corp., is charged with violating the FTC Act by misrepresenting its store credit policy, and the Restore Online Shoppers Confidence Act by failing to provide consumers with a simple mechanism to stop recurring charges. The FTC alleges that for several years the company made it hard to cancel memberships, including by limiting how consumers could submit cancellation requests, under-staffing its customer service department, and putting consumers through drawn-out cancellation request processes. Under the settlement order, the company is prohibited from making misrepresentations in the sale of any good or service with a negative-option feature, and failing to provide a simple way for consumers to avoid being charged and to immediately stop any recurring charges. AdoreMe is also barred from representing that any negative-option feature is being offered on a free, trial, no obligation, reduced, or discounted basis, without clearly disclosing costs and how consumers can avoid charges. In addition, the company must promptly send consumers confirmations of their orders with similar disclosures, without any upsells, additional product or service offers, or other advertising or marketing. The order also prohibits the company from using customers’ billing information to obtain payments without first obtaining their express informed consent in a manner prescribed in the order. The order requires AdoreMe to notify and provide refunds of forfeited store credit to eligible customers, and imposes a $1,378,654 judgment that will be used to pay refunds to consumers under the order. The Commission vote approving the complaint and proposed stipulated order was 2-0. The documents were filed in the U.S. District Court for the Southern District of New York on November 20, 2017. NOTE: Stipulated final orders have the force of law when approved and signed by the District Court judge.